Ferrofluids are nanomaterials consisting of magnetic nanoparticles that are dispersed in a carrier fluid. Their physical properties, and hence their field of application are determined by intertwined compositional, structural, and magnetic characteristics, including interparticle magnetic interactions. Magnetic nanoparticles were prepared by thermal decomposition of iron(III) chloride hexahydrate (FeCl₃·6H₂O) in 2-pyrrolidone, and were then dispersed in two different fluids, water and polyethylene glycol 400 (PEG). A number of experimental techniques (especially, transmission electron microscopy, Mössbauer spectroscopy and superconducting quantum interference device (SQUID) magnetometry) were employed to study both the as-prepared nanoparticles and the ferrofluids. We show that, with the adopted synthesis parameters of temperature and FeCl₃ relative concentration, nanoparticles are obtained that mainly consist of maghemite and present a high degree of structural disorder and strong spin canting, resulting in a low saturation magnetization (~45 emu/g). A remarkable feature is that the nanoparticles, ultimately due to the presence of 2-pyrrolidone at their surface, are arranged in nanoflower-shape structures, which are substantially stable in water and tend to disaggregate in PEG. The different arrangement of the nanoparticles in the two fluids implies a different strength of dipolar magnetic interactions, as revealed by the analysis of their magnetothermal behavior. The comparison between the magnetic heating capacities of the two ferrofluids demonstrates the possibility of tailoring the performances of the produced nanoparticles by exploiting the interplay with the carrier fluid.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707590PMC
http://dx.doi.org/10.3390/nano7110373DOI Listing

Publication Analysis

Top Keywords

carrier fluid
12
interplay carrier
8
magnetic nanoparticles
8
magnetic interactions
8
magnetic
7
nanoparticles
7
synthesis ferrofluids
4
ferrofluids iron
4
iron oxide
4
oxide nanoflowers
4

Similar Publications

Biomarkers.

Alzheimers Dement

December 2024

Neurochemistry Laboratory, Department of Laboratory Medicine, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, North Holland, Netherlands.

Background: The exact mechanism underlying amyloid-related imaging abnormalities (ARIA) is unknown. Several factors explain ARIA risk, including the presence of microbleeds, APOE4 carriership, and very low Aβ42 levels. The cerebrospinal fluid (CSF) proteome reflects ongoing mechanisms and, thereby, provides an accessible fluid to refine risk of ARIA development.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Alamar Biosciences, Fremont, CA, USA.

Background: The development of reliable blood biomarkers for neurodegenerative diseases (NDDs) has been hindered by the lack of tools with sufficient sensitivity to detect low concentrations of brain-derived proteins in plasma or serum in a highly multiplexed manner. NULISA™ (NUcleic acid-Linked Immuno-Sandwich Assay) has emerged as a promising solution, with attomolar sensitivity and capable of high multiplexing in a fully automated system. In this study, we introduce NULISA CNS Disease Panel 120, a 120-plex NULISAseq assay for profiling key hallmarks of NDDs in both blood and cerebrospinal fluid (CSF).

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Department of Neurology & Innovation Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, National Center for Neurological Disorders, Beijing, Beijing, China.

Background: Blood biomarkers provide a non-invasive and accessible means of detection for Alzheimer's disease (AD). Specifically, biomarkers associated with early-onset AD (EOAD) illuminate the underlying mechanisms and provide valuable guidance for potential therapies. We aim to present blood biomarker evidence in individuals with both EOAD and late-onset AD (LOAD), as well as in age-matched healthy controls.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Lund, Sweden.

Background: With the development of disease modifying therapies targeting specific pathologies, accurate in vivo biomarkers have become increasingly important for disease classification. Recently, tests for neuronal α-synuclein (Lewy body) pathology have become available, complementing pre-existing tests for Alzheimer's disease (AD) pathology (Aβ and tau fluid and PET biomarkers) and vascular disease (MRI). Here, we aimed to identify and characterize data-driven pathology-based subtypes using these biomarkers.

View Article and Find Full Text PDF

Background: Obstructive sleep apnea (OSA) is associated with hypoxia-induced neuronal impairment and dysfunction-key risk factors for the pathogeneses of age-related neurodegenerative diseases such as Alzheimer's disease (AD). This study examined longitudinal associations between OSA severity and CSF biomarkers associated with AD, synaptic dysfunction, and neuroinflammation in a sample of late-middle-aged adults with increased risk for AD.

Method: N=25 cognitively unimpaired adults (64% female, mean age 65.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!